Desentum (private company)

See something wrong or missing? Let us know
Offices:Espoo
Industry:BiotechPharma
Business model:B2B

Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergen immunotherapy products that are based on switching the immune system's response to allergens from hypersensitivity to tolerance.

We have a unique approach for designing the hypoallergens used in immunotherapy. By studying the molecular mechanism of the hypersensitivity reaction, we have made discoveries that allow for improved design of immunotherapeutic products against common types of allergies.

Our goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.

Investors: we tracked 5 investors

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

values in USD

Investments 6.41M


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Companies with similar profile to Desentum

Name Criteria
United Kingdom Theolytics
53%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 2
  • At least one other investor: found 1
  • Total raised in a similar range: 5M - 10M USD
Denmark NMD Pharma
52%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 4
  • At least one other investor: found 1
Sweden OxThera
52%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 4
  • At least one other investor: found 1
Spain Sanifit Therapeutics
52%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 4
  • At least one other investor: found 1
Denmark Cytoki Pharma
52%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 3
  • At least one other investor: found 1
United Kingdom Causaly
52%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 3
  • At least one other investor: found 1
Spain Accure Therapeutics
50%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 1
  • At least one other investor: found 1
  • Total raised in a similar range: 5M - 10M USD
Sweden Gradientech
50%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 1
  • At least one other investor: found 1
  • Total raised in a similar range: 5M - 10M USD
United Kingdom ReViral
48%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 2
  • At least one other investor: found 1
Denmark STipe Therapeutics
48%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • At least one vc investor: found 2
  • At least one other investor: found 1
Top